In postmenopausal women with genitourinary syndrome of menopause, pooled vaginal testosterone, systemic DHEA, vaginal oxytocin and oral raloxifene or bazedoxifene may provide no benefit or had uncertain effects.
In plain wordsIn postmenopausal women, a group of treatments that included vaginal oxytocin may give no benefit or had unclear effects on menopause symptoms.
- Peptide
- Oxytocin
- Outcome
- MixedGenitourinary syndrome of menopause symptoms
- Study
n: not reported in source
- Comparator
- Placebo or no treatment
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
Source sentences
Vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene may provide no benefit (low COE) or had uncertain effects (very low COE).
1 context sentence(design, population, supporting numbers)
Randomized controlled trials (RCTs) of at least 8 weeks' duration enrolling postmenopausal women with at least 1 GSM symptom and reporting effectiveness or harms of hormonal interventions or vaginal moisturizers.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.